{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:54:03Z","timestamp":1785873243848,"version":"3.56.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.jpsychires.2013.01.011","type":"journal-article","created":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T22:16:30Z","timestamp":1359584190000},"page":"472-478","source":"Crossref","is-referenced-by-count":27,"title":["Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study"],"prefix":"10.1016","volume":"47","author":[{"given":"Mohammad-Reza","family":"Khodaie-Ardakani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Seddighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Modabbernia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahman","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Ashrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Shams-Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mohammad-Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholam-Reza","family":"Esfandiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Hajiaghaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Akhondzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2013.01.011_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2009.11.008","article-title":"The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial","volume":"116","author":"Abbasi","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib2","first-page":"295","article-title":"The 5-HT hypothesis of schizophrenia","volume":"4","author":"Akhondzadeh","year":"2001","journal-title":"IDrugs"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib3","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.pnpbp.2008.08.001","article-title":"A\u00a012-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia","volume":"32","author":"Akhondzadeh","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00213-010-2044-z","article-title":"Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial","volume":"213","author":"Akhondzadeh","year":"2011","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib5","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.pnpbp.2008.08.020","article-title":"Effect of ritanserin, a 5HT2A\/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study","volume":"32","author":"Akhondzadeh","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.schres.2008.08.004","article-title":"Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial","volume":"107","author":"Akhondzadeh","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hup.902","article-title":"Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study","volume":"23","author":"Amiri","year":"2008","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1345\/aph.1P008","article-title":"The role of ondansetron in the treatment of schizophrenia","volume":"44","author":"Bennett","year":"2010","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2125.1994.tb04397.x","article-title":"Characterisation of the cytochrome P450 enzymes involved in the in\u00a0vitro metabolism of granisetron","volume":"38","author":"Bloomer","year":"1994","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00520-002-0410-z","article-title":"Granisetron: relating pharmacology to clinical efficacy","volume":"11","author":"Blower","year":"2003","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1176\/ajp.154.8.1171a","article-title":"Augmentation of clozapine therapy with ondansetron","volume":"154","author":"Briskin","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0006-3223(97)00388-0","article-title":"The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls","volume":"43","author":"Broocks","year":"1998","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/schbul\/sbl057","article-title":"Persistent negative symptoms in schizophrenia: an overview","volume":"33","author":"Buchanan","year":"2007","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib14","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments","volume":"164","author":"Buchanan","year":"2007","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib15","first-page":"233","article-title":"Extrapyramidal symptom rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Sciences"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/(SICI)1099-1077(200004)15:3<179::AID-HUP156>3.0.CO;2-N","article-title":"Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia","volume":"15","author":"Den Boer","year":"2000","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1192\/bjp.163.4.451","article-title":"Ritanserin, a selective 5-HT2\/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial","volume":"163","author":"Duinkerke","year":"1993","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib18","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archpsyc.1991.01810350018003","article-title":"Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course","volume":"48","author":"Fenton","year":"1991","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/JCP.0b013e3181fa8720","article-title":"A\u00a0double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia","volume":"30","author":"Ghaleiha","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","article-title":"A\u00a0placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia","volume":"56","author":"Goff","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A\u00a0rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-005-0142-0","article-title":"Tropisetron improves deficient inhibitory auditory processing in DBA\/2 mice: role of alpha 7 nicotinic acetylcholine receptors","volume":"183","author":"Hashimoto","year":"2005","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","article-title":"Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia","volume":"56","author":"Heresco-Levy","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.schres.2004.12.016","article-title":"Tropisetron improves deficits in auditory P50 suppression in schizophrenia","volume":"76","author":"Koike","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/138920111794480589","article-title":"Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia","volume":"12","author":"Kucinski","year":"2011","journal-title":"Current Pharmaceutical Biotechnology"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib28","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/schbul\/sbi039","article-title":"Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim","volume":"32","author":"Laughren","year":"2006","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.brainresbull.2003.09.022","article-title":"The effect of ondansetron on memory in schizophrenic patients","volume":"65","author":"Levkovitz","year":"2005","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/(SICI)1098-2396(199807)29:3<257::AID-SYN8>3.0.CO;2-5","article-title":"Inhibition of NMDA-receptor mediated response in the rat medial prefrontal cortical pyramidal cells by the 5-HT3 receptor agonist SR 57227A and 5-HT: intracellular studies","volume":"29","author":"Liang","year":"1998","journal-title":"Synapse"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.psychres.2003.04.001","article-title":"P50 inhibitory gating deficit is correlated with the negative symptomatology of schizophrenia","volume":"136","author":"Louchart-de la","year":"2005","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00213-003-1750-1","article-title":"Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia","volume":"174","author":"Martin","year":"2004","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2006.07.002","article-title":"Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review","volume":"88","author":"Murphy","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/archpsyc.1992.01820090079013","article-title":"Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial","volume":"49","author":"Newcomer","year":"1992","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/FBP.0b013e3282f3cfd4","article-title":"Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models","volume":"19","author":"Ramamoorthy","year":"2008","journal-title":"Behavioral Pharmacology"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1744-859X-9-27","article-title":"A\u00a0randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia","volume":"9","author":"Shiina","year":"2010","journal-title":"Annals of General Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1176\/appi.ajp.157.2.287","article-title":"Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia","volume":"157","author":"Sirota","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib39","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(91)92851-R","article-title":"Ondansetron in treatment of schizophrenia","volume":"337","author":"White","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.brainres.2009.08.075","article-title":"Ondansetron results in improved auditory gating in DBA\/2 mice through a cholinergic mechanism","volume":"1300","author":"Wildeboer","year":"2009","journal-title":"Brain Research"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/YCO.0b013e3283366643","article-title":"Why do patients with schizophrenia smoke?","volume":"23","author":"Winterer","year":"2010","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1016\/j.jpsychires.2013.01.011_bib42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.schres.2006.07.010","article-title":"Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study","volume":"88","author":"Zhang","year":"2006","journal-title":"Schizophrenia Research"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395613000241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395613000241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T12:56:23Z","timestamp":1595336183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395613000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0022395613000241"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2013.01.011","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}